Molecular lung cancer therapy;Molekulare therapie beim lungenkarzinom

Therapeutische Umschau

Volumn 61, Issue 6, 2004, Pages 365-371

  Gautschi, Oliver ^a   Betticher, D C ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AE 941; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BATIMASTAT; BEVACIZUMAB; BEXAROTENE; BMS 27597; BORTEZOMIB; CELECOXIB; CETUXIMAB; DEHYDRODIDEMNIN B; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLAVO; FLAVOPIRIDOL; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; ISIS 3521; LONAFARNIB; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; OBLIMERSEN; PERTUZUMAB; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; TANOMASTAT; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CELL GROWTH; CELL INVASION; CLINICAL TRIAL; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG TARGETING; DYSPEPSIA; EUROPE; FATIGUE; FEVER; GENE THERAPY; HEMOPTYSIS; HUMAN; HYPERLIPIDEMIA; HYPOTHYROIDISM; INFLAMMATION; LUNG CANCER; MOLECULAR BIOLOGY; MUSCLE HYPERTONIA; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; PNEUMONIA; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS;

EID: 3042576499     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.61.6.365     Document Type: Review

References (33)

1. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99-166.
2. Betticher DC. Targeted lung cancer therapy, is there any future? Oncologie 2003; 5: 357-61.
3. Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 2003; 4 (12): 721-9.
4. Moon C, Oh Y, Roth JA. Current status of gene therapy for lung cancer and head and neck cancer. Clin Cancer Res 2003; 9 (14): 5055-67.
5. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000; 18(3): 609-22.
6. Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, Stewart DJ, et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2001; 19 (6): 1750-8.
7. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003; 9 (1): 93-101.
8. Rudin CM, Otterson GA, Mauer AM, Villalona-Calero MA, Tomek R, Prange B, et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002; 13 (4): 539-45.
9. Lynch TJ, Raju R, Lind M, Riviere A, Gatzemeier U, Drorr A, et al. Randomized Phase III Trial of Chemotherapy and Antisense Olignucleotide LY900003 (ISIS 3521) in Patients with Advanced NSCLC: Initial Report. Proc Am Soc Clin Oncol 2003; Abstract 2504.
10. Stahel RA, Zangemeister-Wittke U. Antisense oligonucleotides for cancer therapy - an overview. Lung Cancer 2003; 41 Suppl 1: 81-8.
11. DeVore R, Fehrenbacher L, Herbst RS, Langer C, Kelly K, Gaudreault J, et al. A randomized phase II trial comparing rhumab VEGF (vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 2000; 19, Abstract 1896.
12. Sridhar SS, Shepherd FA. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2003; 42 (2 Suppl): 81-91.
13. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 2002; 29 (1 Suppl 4): 78-86.
14. Latreille J, Batist G, Laberge F, Champagne P, Croteau D, Falardeau P, et al. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer 2003; 4 (4): 231-6.
15. Janne PA. The role of epidermal growth factor receptor in advanced non-small cell lung carcinoma. Ann Med 2003; 35 (7): 450-7.
16. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 2003; 4 (7): 397-406.
17. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res. 1999; 5 (4): 909-16.
18. Kim ES, Maurer AM, Fossella F, Jamison TA, Kies MS, Pisters KM, et al. A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21, Abstract 1168.
19. Gatzemeier U, Rosell R, Ramlau R, Robinet G, Szczesna A, Quoix E, et al. Cetuximab (C225) in combination with cisplatin/vinorelbine vs. cisplatin/vinorelbine alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR) positive advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003: 642, Abstract 2582.
20. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004; 15 (1): 19-27.
21. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003; 532: 253-68.
22. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20 (18): 3815-25.
23. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21 (12): 2237-46.
24. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. A phase II trial of ZD1839 ("Iressa") in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002; Abstract 1166.
25. Giaccone G, Johnson D, Scagliotti GV, Manegold C, Rosell R, Rennie P, et al. Results of a multivariate analysis of prognostic factors of overall survival of patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (ZD1839) in combination with platinum-based chemotherapy (CT) in two large phase III trials (INTACT 1 and 2). Proc Am Soc Clin Oncol 2003; 627, Abstract 2522.
26. Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond 1, et al. A Phase II Trial of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor OSI-774, Following Platinum-Based Chemotherapy, in Patients (pts) with Advanced, EGFR-Expressing, Non-Small Cell Lung Cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20, Abstract 1235.
27. Miller VA, Patel J, Shah N, Kris MG, Tyson L, Pizzo B, et al. The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma (BAC): Preliminary results of a phase II trial. Proc Am Soc Clin Oncol 2003; 22, Abstract 2491.
28. Johnston SR. Famesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet Oncol 2001; 2 (1): 18-26.
29. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003 29; 22 (42): 6609-20.
30. Mack PC, Davies AM, Lara PN, Gumerlock PH, Gandara DR. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer 2003; 41 Suppl 1: 89-96.
31. (no authors listed) Current Data with Bexarotene (Targretin) in Non-Small-Cell Lung Cancer. Clin Lung Cancer 2003; 4 (4): 210-2.
32. Laskin JJ, Sandler AB. The importance of the eicosanoid pathway in lung cancer. Lung Cancer 2003; 41 Suppl 1: 73-9.
33. Nemunaitis J. Granulocyte-macrophage colony-stimulating factor gene-transfected autologous tumor cell vaccine: focus on non-small-cell lung cancer. Clin Lung Cancer 2003; 5 (3): 148-57.